Sequana Medical NV
XBRU:SEQUA

Watchlist Manager
Sequana Medical NV Logo
Sequana Medical NV
XBRU:SEQUA
Watchlist
Price: 0.85 EUR -1.16% Market Closed
Market Cap: 34.4m EUR
Have any thoughts about
Sequana Medical NV?
Write Note

Sequana Medical NV
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sequana Medical NV
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Sequana Medical NV
XBRU:SEQUA
Cash from Financing Activities
€12.7m
CAGR 3-Years
-22%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Nyxoah SA
XBRU:NYXH
Cash from Financing Activities
€16.9m
CAGR 3-Years
-45%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Biocartis Group NV
XBRU:BCART
Cash from Financing Activities
€61.7m
CAGR 3-Years
N/A
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Ion Beam Applications SA
XBRU:IBAB
Cash from Financing Activities
-€14.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sequana Medical NV
Glance View

Market Cap
34.4m EUR
Industry
Health Care

Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 60 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.

SEQUA Intrinsic Value
1.69 EUR
Undervaluation 50%
Intrinsic Value
Price

See Also

What is Sequana Medical NV's Cash from Financing Activities?
Cash from Financing Activities
12.7m EUR

Based on the financial report for Jun 30, 2024, Sequana Medical NV's Cash from Financing Activities amounts to 12.7m EUR.

What is Sequana Medical NV's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-16%

Over the last year, the Cash from Financing Activities growth was -47%. The average annual Cash from Financing Activities growth rates for Sequana Medical NV have been -22% over the past three years , -16% over the past five years .

Back to Top